|Podcasts|September 20, 2022
The Oncologist: Patient Conversation Must Include Clinical Trials
Author(s)Lisa Henderson, Andy Studna, Senior Editor
Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.
This podcast sponosored by
Related Content
Trending on Applied Clinical Trials Online
1
The Handoff Illusion: Why Clean Transitions in Clinical Development Are a Myth
2
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
3
ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism
4
Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value
5